GSK campaign promotes cervical cancer awareness
PHILADELPHIA —A young woman sits in a restaurant waiting for her friends, excited about a night out on the town.
“Where RU and Lucy?!” she writes in a text message.
“Lucy’s not coming,” her friend replies.
“What a wimp!” the woman texts back.
“She just found out she has cervical cancer,” her friend writes in return, as the smile melts off the woman’s face, replaced by a look of shock and worry.
The video is one of many that GlaxoSmithKline has created as part of an information campaign to raise awareness about cervical cancer, along with the Web site HelpPreventCervicalCancer.com. GSK markets the human papillomavirus and cervical cancer vaccine Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant). The British drug maker is one of two companies that make HPV vaccines, the other being Merck’s Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant).
According to the GSK campaign, a woman in the United States is diagnosed with cervical cancer every 47 minutes, and it is the second most common cause of cancer-related death in women in their 20s and 30s.
Schnucks’ O’Brien to serve on Department of Agriculture advisory committee
ST. LOUIS An executive from Schnuck Markets will serve on an advisory committee of the Department of Agriculture, Schnucks said this week.
Agriculture secretary Tom Vilsack announced that Schnucks VP produce and floral Mike O’Brien would be one of 25 people appointed to a two-year term on the USDA’s Fruit and Vegetable Industry Advisory Committee. O’Brien is also vice chairman of the Produce Marketing Association.
“I am honred to represent Schnuck Markets and the retail produce industry as a member of this committee,” O’Brien said. “I am looking forward to the opportunity to contribute and to make a difference for families across the nation.”
The committee, originally chartered in 2001, advises the secretary of agriculture on industry issues related to fruits and vegetables.
Gilead commences phase 3 trial for single-tablet HIV treatment
FOSTER CITY, Calif. Gilead Sciences has started a late-stage clinical trial of an investigational 4-in-1 treatment for HIV, the drug maker said.
Gilead announced the initiation of a phase 3 trial of its “Quad” HIV drug, a single-tablet treatment that combines elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The study will compare the Quad regimen with the standard of care among adults with HIV-1 who have not taken antiretroviral treatments. The company is also investigating cobicistat as a standalone boosting agent for antiretroviral drugs.
“We are pleased to announce that the Quad phase 3 clinical program is underway,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said. “Efficacy and safety results from the phase 2 study suggest that the Quad may represent an important new option for patients with HIV.”